Tsumura and Co (4540:TYO) - Strategic SWOT and Financial Analysis - A Review of Opportunities, Challenges and Risk, Corporate and ESG Strategies, Competitive Intelligence and Financial and Operational KPIs, and Recent Trends
Report Summary Tsumura & Co Strategic SWOT Analysis and Financial Insights - A 360° Review of Opportunities, Challenges and Risk, Corporate and ESG Strategies, Competitive Intelligence, and Rece... もっと見る
日本語のページはAI翻訳を利用し作成しています。
SummaryReport SummaryTsumura & Co Strategic SWOT Analysis and Financial Insights - A 360° Review of Opportunities, Challenges and Risk, Corporate and ESG Strategies, Competitive Intelligence, and Recent Trends Report is a comprehensive and easily accessible overview of Tsumura & Co's business operations. It provides a detailed analysis of the company's financial and strategic standing, as well as its position in the industry compared to competitors. The report includes several key features to facilitate decision-making and provide insights into the company's performance. The report begins with in-depth information about Tsumura & Co including key insights, business segments, key executives, locations, products and services, historical events, corporate strategy, and management discussions. This section provides a solid foundation for understanding the company's key attributes. Next, the report assesses Tsumura & Co's strategic standing through various analyses. The ESG spotlight evaluates the company's environmental, social, and governance performance, providing insights into its sustainability efforts and ethical practices. The SWOT analysis examines the company's internal strengths and weaknesses, as well as external opportunities and threats. Additionally, By integrating these strategic analyses, the report offers a comprehensive understanding of Tsumura & Co's overall strategic standing and supports informed decision-making and strategic planning. The report also covers Tsumura & Co's financial analysis basis of latest income statement, balance sheet, and cash flow statement. Key financial ratios related to profitability, asset turnover, credit, market, and long-term solvency are outlined, providing guidance for investment decisions. Furthermore, the report compares Tsumura & Co's financial parameters with those of its competitors, offering a unique analysis of the competitive landscape. This information helps manage the business environment and improve sales activities by gaining insight into competitors' operations. Finally, the report includes recent news and deal activities undertaken by Tsumura & Co enhancing awareness of the company's business trends, growth perspectives, and more. Key Highlights Tsumura & Co., incorporated on 1893 by Jusha Tsumura in Tokyo, Japan. Headquartered at 2-17-11 Akasaka, Minato-ku, Tokyo, Japan, the company has grown into a leader in the pharmaceutical sector, specializing in Kampo medicines traditional Japanese herbal formulations derived from natural crude drugs. Operating primarily in healthcare and drug manufacturing, Tsumura focuses on producing Kampo extract intermediates, granular formulations, prescription drugs, over-the-counter medicines, and health foods targeting conditions like fatigue, gastrointestinal issues, stress, and women's health. Its commitment to blending ancient herbal practices with modern scientific research drives innovation, with significant R&D investment supporting over 140 Kampo products. Tsumura maintains a strong presence in Asia, particularly Japan, China, and South Korea, where it exports Kampo medicines and operates subsidiaries like Tsumura China Inc. and Ping An Tsumura Inc. for procurement and research. Overseas sales, accounting for about 15% of revenue, extend to North America and Europe, reflecting growing global demand for natural healthcare solutions. With 4,272 consolidated employees as of March 2025 and listing on the Tokyo Stock Exchange (ticker: 4540), Tsumura continues advancing wellness through quality and sustainability. Tsumura & Co in the News:- 2025-06-18 - Notice regarding the conclusion of an agreement for Tsumura China Inc. to acquire an interest in Shanghai Hongqiao Traditional Chinese Drug Pieces Co., Ltd 2025-05-12 - Notice regarding the continuation of Trust-type Stock Delivery System for Employees 2025-02-06 - Tsumura Announces Conclusion of Letter of Intent between Ping An Tsumura Inc. and Shanghai Hongqiao Pharmaceutical Co., Ltd. Scope • Tactical Analysis:- Various strategic frameworks to gain insights into a Tsumura & Co's competitive position and operational environment. These analytical tools assist in identifying competitive advantages, potential risks, and areas for improvement and efficiency, enabling companies to make informed tactical decisions. • Business Strategy:- Contributes to shaping the Tsumura & Co's overall direction, goals, and decision-making processes, ensuring long-term success and alignment with stakeholder expectations. • Financial Position:- Provide valuable information on the financial performance and investor sentiment surrounding the company. Indicating the level of confidence and expectations in the company's future prospects. These components collectively contribute to understanding the financial health and market perception of the company. • Company Fundamentals:- These fundamentals offer valuable insights into the company's history, operations, leadership, and geographical presence, aiding in a comprehensive understanding of the organization. • Competitive Landscape:- An identification of the Tsumura & Co's main competitors, providing insights into the competitive landscape it operates in. Reasons to Buy • Comprehensive Understanding of the Tsumura & Co's internal and external factors through SWOT analysis, Financial Analysis, and Competitors Benchmarking. • Strive Strategic Decision Making with various analyses and identifying potential customers and suppliers. • Mitigate Risk with help of thorough analysis of internal and external factors. Furthermore, develop strategies and contingency plans to address these challenges and minimize their impact on business operations. • Competitive Benchmarking will help to gain a competitive advantage by understanding industry trends, customer preferences, and best practices. • Financial Performance Evaluation provides crucial insights into key financial ratios and trends, supporting better financial decision-making and resource allocation. • Valuable insights from the report enable investors and partners to make informed decisions regarding potential Collaborations, Investments, or Partnerships with the company. Additionally, available deep-dive analysis on the company Tsumura & Co: • Tsumura & Co PESTLE Analysis • Tsumura & Co Value Chain Analysis • Tsumura & Co Porter's Five Forces Analysis • Tsumura & Co VRIO Analysis • Tsumura & Co BCG Analysis • Tsumura & Co Segmentation, Targeting and Positioning (STP) Analysis • Tsumura & Co Ansoff Matrix Analysis Table of ContentsTable of Contents 2Tables 5 Charts 6 Tsumura & Co - Key Company Facts 7 Tsumura & Co - Company Description 8 Tsumura & Co - Top Executives 9 Tsumura & Co - Head Office & Locations 10 Head Office - Country 10 Tsumura & Co - Products and Services 11 Products 11 Services 12 Tsumura & Co - Corporate Strategy 13 Tsumura & Co - Business Description 17 Sales of Pharmaceutical Products 18 Tsumura & Co - ESG Spotlight 20 Environment 20 Social 21 Corporate Governance 21 Tsumura & Co - SWOT Analysis 23 Overview 23 Strengths 25 Weaknesses 27 Opportunities 29 Threats 31 Tsumura & Co - Financial Deep Dive 33 Share Price Trend - Jun-2025 to Jun-2026 (Average Share Closing Price) 33 Profit and Loss Statement 35 Summary of Profit and Loss Statement 35 Balance Sheet 39 Summary of Balance Sheet 39 Cash Flow Statement 43 Summary of Cash Flow Statement 43 Key Financial Ratio Analysis 47 Tsumura & Co - Ratio Charts 49 Activity Ratio Charts 49 Growth Ratios Charts 50 Leverage Ratio Charts 54 Liquidity Ratio Charts 56 Profitability Ratio Charts 58 Competing Players 60 Snapshot of Competing Players 61 Hisamitsu Pharmaceutical Co Inc 61 Key Company Facts 61 Company Description 61 Key Financials 62 Share Price Trend - Jun-2025 to May-2026 (Average Share Closing Price) 62 Key Financial Ratio Analysis 67 Kobayashi Pharmaceutical Co Ltd 69 Key Company Facts 69 Company Description 69 Key Financials 70 Share Price Trend - Jun-2025 to Jun-2026 (Average Share Closing Price) 70 Key Financial Ratio Analysis 75 Yakult Honsha Co., Ltd 77 Key Company Facts 77 Company Description 77 Key Financials 78 Share Price Trend - Jun-2025 to Jun-2026 (Average Share Closing Price) 78 Key Financial Ratio Analysis 83 Kracie, Ltd 85 Key Company Facts 85 Company Description 85 Tsumura & Co - In the News 86 18-Jun-2025 - Notice regarding the conclusion of an agreement for Tsumura China Inc. to acquire an interest in Shanghai Hongqiao Traditional Chinese Drug Pieces Co., Ltd 86 Appendix 87 Definitions 87 SWOT Analysis 87 PESTLE Analysis 87 Value Chain Analysis 87 ESG Spotlight 87 Financial Deep Dive 87 Financial Ratios 88 Activity Ratios 88 Growth Ratios 90 Leverage Ratios 93 Liquidity Ratios 95 Market Ratios 97 Profitability Ratios 99 Research Methodology 101 Disclaimer 102 Contact Us 102
ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。本レポートと同分野(医療/ヘルスケア)の最新刊レポート
Quaintel Research社の 医薬品・医療分野 での最新刊レポート
本レポートと同じKEY WORD(corporate)の最新刊レポート
よくあるご質問Quaintel Research社はどのような調査会社ですか?Quaintel Researchはインドを拠点をとする調査会社です。 様々な企業の分析を行っており、企業の競合分析に役立つ資料をご提供します。 もっと見る 調査レポートの納品までの日数はどの程度ですか?在庫のあるものは速納となりますが、平均的には 3-4日と見て下さい。
注文の手続きはどのようになっていますか?1)お客様からの御問い合わせをいただきます。
お支払方法の方法はどのようになっていますか?納品と同時にデータリソース社よりお客様へ請求書(必要に応じて納品書も)を発送いたします。
データリソース社はどのような会社ですか?当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
|
|